Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients

Abstract

The direct medical costs of newly-diagnosed, TMZ-treated GBM in commercially insured patients are substantial, with estimated total cumulative costs of $268,031.